183 related articles for article (PubMed ID: 35898339)
21. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
22. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
23. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
[TBL] [Abstract][Full Text] [Related]
24. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38761806
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
[TBL] [Abstract][Full Text] [Related]
26. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.
COVID-19 Forecasting Team
Lancet; 2023 Mar; 401(10379):833-842. PubMed ID: 36930674
[TBL] [Abstract][Full Text] [Related]
27. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai.
Fu Z; Liang D; Zhang W; Shi D; Ma Y; Wei D; Xi J; Yang S; Xu X; Tian D; Zhu Z; Guo M; Jiang L; Yu S; Wang S; Jiang F; Ling Y; Wang S; Chen S; Liu F; Tan Y; Fan X
Front Med; 2023 Jun; 17(3):562-575. PubMed ID: 36949347
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic and Effective Severity of Coronavirus Disease 2019 Cases Infected With the Ancestral Strain and Omicron BA.2 Variant in Hong Kong.
Wong JY; Cheung JK; Lin Y; Bond HS; Lau EHY; Ip DKM; Cowling BJ; Wu P
J Infect Dis; 2023 Nov; 228(9):1231-1239. PubMed ID: 37368235
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
[TBL] [Abstract][Full Text] [Related]
31. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
[TBL] [Abstract][Full Text] [Related]
32. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.
Lewnard JA; Hong VX; Patel MM; Kahn R; Lipsitch M; Tartof SY
Nat Med; 2022 Sep; 28(9):1933-1943. PubMed ID: 35675841
[TBL] [Abstract][Full Text] [Related]
34. Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: an observational study.
Yang B; Lin Y; Xiong W; Liu C; Gao H; Ho F; Zhou J; Zhang R; Wong JY; Cheung JK; Lau EHY; Tsang TK; Xiao J; Wong IOL; Martín-Sánchez M; Leung GM; Cowling BJ; Wu P
Lancet Reg Health West Pac; 2024 Feb; 43():100969. PubMed ID: 38076326
[TBL] [Abstract][Full Text] [Related]
35. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
36. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study.
Jassat W; Abdool Karim SS; Mudara C; Welch R; Ozougwu L; Groome MJ; Govender N; von Gottberg A; Wolter N; Wolmarans M; Rousseau P; ; Blumberg L; Cohen C
Lancet Glob Health; 2022 Jul; 10(7):e961-e969. PubMed ID: 35597249
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
38. Age-specific transmission dynamics under suppression control measures during SARS-CoV-2 Omicron BA.2 epidemic.
Zhu W; Wen Z; Chen Y; Gong X; Zheng B; Liang X; Xu A; Yao Y; Wang W
BMC Public Health; 2023 Apr; 23(1):743. PubMed ID: 37087436
[TBL] [Abstract][Full Text] [Related]
39. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
40. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S
Front Immunol; 2023; 14():1290279. PubMed ID: 38259438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
